open access

Vol 12, No 2 (2018)
Review paper
Published online: 2018-06-06
Get Citation

The use of opioids in the treatment of non-neoplastic pulmonary diseases

Magdalena Renata Osowicka, Piotr Janowiak, Agnieszka Gorzewska
Palliat Med Pract 2018;12(2):118-126.

open access

Vol 12, No 2 (2018)
Review articles
Published online: 2018-06-06


Abstract Studies on the endogenous opioid system have demonstrated its presence, including opioid receptors, not only in the central nervous system but also in the respiratory tract. The presence of these receptors, both centrally and peripherally, provides the potential for treatment of respiratory symptoms, such as dyspnea and cough, with systemic and local application of opioids. These are especially important when symptomatic treatment becomes a priority in patient care.


Abstract Studies on the endogenous opioid system have demonstrated its presence, including opioid receptors, not only in the central nervous system but also in the respiratory tract. The presence of these receptors, both centrally and peripherally, provides the potential for treatment of respiratory symptoms, such as dyspnea and cough, with systemic and local application of opioids. These are especially important when symptomatic treatment becomes a priority in patient care.
Get Citation


opioids, dyspnoea, cough, palliative care, lung disease

About this article

The use of opioids in the treatment of non-neoplastic pulmonary diseases


Palliative Medicine in Practice


Vol 12, No 2 (2018)

Article type

Review paper



Published online


Bibliographic record

Palliat Med Pract 2018;12(2):118-126.


palliative care
lung disease


Magdalena Renata Osowicka
Piotr Janowiak
Agnieszka Gorzewska

References (98)
  1. Uronis HE, Currow DC, Abernethy AP. Palliative management of refractory dyspnea in COPD. Int J Chron Obstruct Pulmon Dis. 2006; 1(3): 289–304.
  2. Jassem E, Batura-Gabryel H, Cofta S, et al. Polskie Towarzystwo Chorób Płuc. [Reccomendation of Polish Respiratory Society for palliative care in chronic lung diseases]. Pneumonol Alergol Pol. 2012; 80(1): 41–64.
  3. Vigeland CL, Hughes AH, Horton MR. Etiology and treatment of cough in idiopathic pulmonary fibrosis. Respir Med. 2017; 123: 98–104.
  4. Vicent L, Olarte JM, Puente-Maestu L, et al. Hospital without dyspnea: rationale and design of a multidisciplinary intervention. J Geriatr Cardiol. 2016; 13(7): 625–631.
  5. Damps-Konstańska I, Werachowska L, Krakowiak P, et al. Acceptance of home support and integrated care among advanced COPD patients who live outside large medical centers. Appl Nurs Res. 2016; 31: 60–64.
  6. Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J. 2009; 33(4): 771–777.
  7. Gifford AH, Mahler DA, Waterman LA, et al. Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD. 2011; 8(3): 160–166.
  8. Bellofiore S, Di Maria GU, Privitera S, et al. Endogenous opioids modulate the increase in ventilatory output and dyspnea during severe acute bronchoconstriction. Am Rev Respir Dis. 1990; 142(4): 812–816.
  9. Pattinson KTS. Opioids and the control of respiration. Br J Anaesth. 2008; 100(6): 747–758.
  10. Baumgärtner U, Buchholz HG, Bellosevich A, et al. High opiate receptor binding potential in the human lateral pain system. Neuroimage. 2006; 30(3): 692–699.
  11. Pattinson KTS, Johnson MJ. Neuroimaging of central breathlessness mechanisms. Curr Opin Support Palliat Care. 2014; 8(3): 225–233.
  12. von Leupoldt A, Sommer T, Kegat S, et al. Dyspnea and pain share emotion-related brain network. Neuroimage. 2009; 48(1): 200–206.
  13. Parshall MB, Schwartzstein RM, Adams L, et al. American Thoracic Society Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012; 185(4): 435–452.
  14. Mahler DA. Opioids for refractory dyspnea. Expert Rev Respir Med. 2013; 7(2): 123–34; quiz 135.
  15. Ekström M, Nilsson F, Abernethy AA, et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc. 2015; 12(7): 1079–1092.
  16. Jennings AL, Davies AN, Higgins JPT, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002; 57(11): 939–944.
  17. Estfan B, Mahmoud F, Shaheen P, et al. Respiratory function during parenteral opioid titration for cancer pain. Palliat Med. 2007; 21(2): 81–86.
  18. Clemens KE, Klaschik E. Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage. 2007; 33(4): 473–481.
  19. Colasanti A, Rabiner EA, Lingford-Hughes A, et al. Opioids and anxiety. J Psychopharmacol. 2011; 25(11): 1415–1433.
  20. Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000; 66(23): 2221–2231.
  21. Krajnik M, Jassem E, Sobanski P. Opioid receptor bronchial tree: current science. Curr Opin Support Palliat Care. 2014; 8(3): 191–199.
  22. Krajnik M, Podolec Z, Siekierka M, et al. Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain Symptom Manage. 2009; 38(5): 747–757.
  23. Lee AL, Harrison SL, Goldstein RS, et al. Pain and its clinical associations in individuals with COPD: a systematic review. Chest. 2015; 147(5): 1246–1258.
  24. Belvisi MG, Hele DJ. Cough sensors. III. Opioid and cannabinoid receptors on vagal sensory nerves. Handb Exp Pharmacol. 2009(187): 63–76.
  25. Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010; 137(3): 674–691.
  26. GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2017. Pneumologie. 2017; 71(01): 9–14.
  27. Marciniuk DD, Goodridge D, Hernandez P, et al. Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011; 18(2): 69–78.
  28. Molassiotis A, Bailey C, Caress A, et al. Interventions for cough in cancer. Cochrane Database Syst Rev. 2010(9): CD007881.
  29. Wee B, Browning J, Adams A, et al. Management of chronic cough in patients receiving palliative care: review of evidence and recommendations by a task group of the Association for Palliative Medicine of Great Britain and Ireland. Palliat Med. 2012; 26(6): 780–787.
  30. Yancy WS, McCrory DC, Coeytaux RR, et al. Efficacy and tolerability of treatments for chronic cough: a systematic review and meta-analysis. Chest. 2013; 144(6): 1827–1838.
  31. Morice AH, McGarvey L, Pavord I, et al. British Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adults. Thorax. 2006; 61 Suppl 1: i1–24.
  32. Molassiotis A, Smith J, Mazzone P, et al. Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer. Chest. 2017; 151(4): 861–874.
  33. Życzkowska J, Wordliczek J. Podskórne i dożylne stosowanie leków przeciwbólowych w medycynie paliatywnej. Med Paliatywna w Prakt. 2010; 4: 6–13.
  34. De Walden-Gałuszko K, Ciałkowska-Rysz A. Medycyna paliatywna. PZWL, Warszawa 2015.
  35. Simon ST, Niemand AM, Benalia H, et al. Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med. 2012; 15(12): 1374–1381.
  36. Jensen D, Alsuhail A, Viola R, et al. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage. 2012; 43(4): 706–719.
  37. Masood AR, Thomas SH. Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. Br J Clin Pharmacol. 1996; 41(3): 250–252.
  38. Davis C, Lam W, Butcher M, et al. Low systemic bioavailability of nebulized morphine: potential therapeutic role for the relief of dyspnoea. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1992: 359.
  39. Hung OR, Whynot SC, Varvel JR, et al. Pharmacokinetics of inhaled liposome-encapsulated fentanyl. Anesthesiology. 1995; 83(2): 277–284.
  40. Macleod DB, Habib AS, Ikeda K, et al. Inhaled fentanyl aerosol in healthy volunteers: pharmacokinetics and pharmacodynamics. Anesth Analg. 2012; 115(5): 1071–1077.
  41. Ward ME, Woodhouse A, Mather LE, et al. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin Pharmacol Ther. 1997; 62(6): 596–609.
  42. Quigley C, Joel S, Patel N, et al. A phase I/II study of nebulized morphine-6-glucuronide in patients with cancer-related breathlessness. J Pain Symptom Manage. 2002; 23(1): 7–9.
  43. Zeppetella G. Nebulized morphine in the palliation of dyspnoea. Palliat Med. 1997; 11(4): 267–275.
  44. Tanaka K, Shima Y, Kakinuma R, et al. Effect of nebulized morphine in cancer patients with dyspnea: a pilot study. Jpn J Clin Oncol. 1999; 29(12): 600–603.
  45. Tooms A, McKenzie A, Grey H. Nebulised morphine. The Lancet. 1993; 342(8879): 1123–1124.
  46. Noseda A, Carpiaux JP, Markstein C, et al. Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J. 1997; 10(5): 1079–1083.
  47. Masood AR, Reed JW, Thomas SH. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax. 1995; 50(6): 629–634.
  48. Harris-Eze AO, Sridhar G, Clemens RE, et al. Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med. 1995; 152(6 Pt 1): 1940–1945.
  49. Jankelson D, Hosseini K, Mather LE, et al. Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J. 1997; 10(10): 2270–2274.
  50. Beauford W, Saylor TT, Stansbury DW, et al. Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest. 1993; 104(1): 175–178.
  51. Leung R, Hill P, Burdon J. Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax. 1996; 51(6): 596–600.
  52. Young IH, Daviskas E, Keena VA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax. 1989; 44(5): 387–390.
  53. Shohrati M, Ghanei M, Harandi AA, et al. Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study. Pulm Med. 2012; 2012: 610921.
  54. Bruera E, Sala R, Spruyt O, et al. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005; 29(6): 613–618.
  55. Farncombe M, Chater S, Gillin A. The use of nebulized opioids for breathlessness: a chart review. Palliat Med. 1994; 8(4): 306–312.
  56. Farncombe M, Chater S. Case studies outlining use of nebulized morphine for patients with end-stage chronic lung and cardiac disease. J Pain Symptom Manage. 1993; 8(4): 221–225.
  57. Farncombe M, Chater S. Clinical application of nebulized opioids for treatment of dyspnoea in patients with malignant disease. Support Care Cancer. 1994; 2(3): 184–187.
  58. Cohen SP, Dawson TC. Nebulized morphine as a treatment for dyspnea in a child with cystic fibrosis. Pediatrics. 2002; 110(3): e38.
  59. Janahi IA, Maciejewski SR, Teran JM, et al. Inhaled morphine to relieve dyspnea in advanced cystic fibrosis lung disease. Pediatr Pulmonol. 2000; 30(3): 257–259.
  60. Davis C, Penn K, et al. A’Hern R, Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliat Med. 1996; 10: 64–65.
  61. Davis C, Hodder C, Love S, et al. Effect of nebulised morphine and morphine-6-glucuronide on exercise endurance in patients with chronic obstructive pulmonary disease. Thorax. 1994; 49: 393.
  62. Sarhill N, Walsh D, Khawam E, et al. Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. Am J Hosp Palliat Care. 2000; 17(6): 389–391.
  63. Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage. 2008; 36(1): 29–38.
  64. Graff GR, Stark JM, Grueber R. Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient. Respiration. 2004; 71(6): 646–649.
  65. Coyne P, Viswanathan R, Smith T. Nebulized Fentanyl Citrate Improves Patients' Perception of Breathing, Respiratory Rate, and Oxygen Saturation in Dyspnea. Journal of Pain and Symptom Management. 2002; 23(2): 157–160.
  66. Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care. 2007; 52(7): 900–910.
  67. Barnes H, McDonald J, Smallwood N, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016; 3: CD011008.
  68. Janowiak P, Krajnik M, Podolec Z, et al. Dosimetrically administered nebulized morphine for breathlessness in very severe chronic obstructive pulmonary disease: a randomized, controlled trial. BMC Pulm Med. 2017; 17(1): 186.
  69. Rutherford RM, Azher T, Gilmartin JJ. Dramatic response to nebulized morphine in an asthmatic patient with severe chronic cough. Ir Med J. 2002; 95(4): 113–114.
  70. Stein WM, Min YK. Nebulized morphine for paroxysmal cough and dyspnea in a nursing home resident with metastatic cancer. Am J Hosp Palliat Care. 1997; 14(2): 52–56.
  71. An HoJ, Kim IK, Lee JE, et al. Nebulized morphine for intractable cough in advanced cancer: two case reports. J Palliat Med. 2015; 18(3): 278–281.
  72. Viola R, Bak K, Cathy K, et al. Cancer Care Ontario’s Symptom Management Guide-to-Practice: Dyspnoea. 2017.
  73. Hui D, Xu A, Frisbee-Hume S, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. J Pain Symptom Manage. 2014; 47(2): 209–217.
  74. Hui D, Kilgore K, Park M, et al. Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial. J Pain Symptom Manage. 2016; 52(4): 459–468.e1.
  75. Hui D, Kilgore K, Frisbee-Hume S, et al. Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial. J Pain Symptom Manage. 2017; 54(6): 798–805.
  76. Simon ST, Kloke M, Alt-Epping B, et al. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. J Pain Symptom Manage. 2016; 52(5): 617–625.
  77. Juan G, Ramón M, Valia JC, et al. Palliative treatment of dyspnea with epidural methadone in advanced emphysema. Chest. 2005; 128(5): 3322–3328.
  78. Shinjo T, Okada M. [Efficacy of controlled-release oxycodone for dyspnea in cancer patients--three case series]. Gan To Kagaku Ryoho. 2006; 33(4): 529–532.
  79. Tanaka M, Maeba H, Senoo T, et al. Efficacy of Oxycodone for Dyspnea in End-stage Heart Failure with Renal Insufficiency. Intern Med. 2018; 57(1): 53–57.
  80. Gajewski P, Szczeklik A. Interna Szczeklika. Medycyna Praktyczna, Kraków 2017.
  81. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011; 42(3): 388–399.
  82. Booth S, Bausewein C, Higginson I, et al. Pharmacological treatment of refractory breathlessness. Expert Rev Respir Med. 2009; 3(1): 21–36.
  83. Varkey B. Opioids for palliation of refractory dyspnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2010; 16(2): 150–154.
  84. Leppert W. The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities. Contemp Oncol (Pozn). 2012; 16(2): 125–131.
  85. Yamanaka T, Sadikot RT. Opioid effect on lungs. Respirology. 2013; 18(2): 255–262.
  86. Cheatle MD, Webster LR. Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies. Pain Med. 2015; 16 Suppl 1: S22–S26.
  87. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage. 2002; 23(4): 278–291.
  88. Baldo BA, Pham NH. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesth Intensive Care. 2012; 40(2): 216–235.
  89. Webster LR. Eight principles for safer opioid prescribing. Pain Med. 2013; 14(7): 959–961.
  90. Parmar MS. Exacerbation of asthma secondary to fentanyl transdermal patch. BMJ Case Rep. 2009; 2009.
  91. Gaspar C, Alfarroba S, Telo L, et al. End-of-life care in COPD: a survey carried out with Portuguese pulmonologists. Rev Port Pneumol. 2014; 20(3): 123–130.
  93. Janssen DJA, de Hosson SM, bij de Vaate E, et al. Attitudes toward opioids for refractory dyspnea in COPD among Dutch chest physicians. Chron Respir Dis. 2015; 12(2): 85–92.
  94. Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014; 348: g445.
  95. Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2016; 48(3): 683–693.
  96. Neutel CI, Johansen HL. Association between hypnotics use and increased mortality: causation or confounding? Eur J Clin Pharmacol. 2015; 71(5): 637–642.
  97. Thorns A, Sykes N. Opioid use in last week of life and implications for end-of-life decision-making. Lancet. 2000; 356(9227): 398–399.
  98. Chan JD, Treece PD, Engelberg RA, et al. Narcotic and benzodiazepine use after withdrawal of life support: association with time to death? Chest. 2004; 126(1): 286–293.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Medycyna Paliatywna w Praktyce dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: